A study of a GLP-1 medicine, semaglutide, in people with heart failure with preserved ejection fraction.
Recruiting now. Registry record last updated August 11, 2026.
- Who can join
- Adults 18 to 90, have heart failure with preserved ejection fraction.
- What you take
- Semaglutide, given as part of the study. Check ClinicalTrials.gov for this trial's study groups, including any placebo or comparison medicine.
- How long it lasts
- The full study runs about 4 years.
- What you get
- Costs vary by study. Ask the study team what this one covers, including the study medicine, visits and travel, before you sign the consent form.
What this study is for
Primary condition: Heart Failure Preserved Ejection Fraction. Also studied in: Epicardial Adipose Tissue.
Full scientific study title: Epicardial Adipose Tissue Composition and Heart Failure With Preserved Ejection Fraction.
Who can join
Adults 18 to 90, have heart failure with preserved ejection fraction. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.
Full medical eligibility (for you and your doctor)verbatim from the registry
This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.
Key inclusion criteria
- Age ≥ 18 years - 90 years;
- LVEF ≥ 50%;
- ≥ 2 risk factors for HFpEF or symptoms that could be related to HFpEF (e.g., dyspnea, orthopnea, paroxysmal nocturnal dyspnea, lower extremity edema, pulmonary edema, etc);
- Not currently being treated with GLP-1RA therapy.
Key exclusion criteria
- • Previously or currently reduced EF (\<50%), including heart transplant; (2) Obstructive un-revascularized coronary disease by coronary CT or invasive coronary angiography;
- MI/PCI/CABG within the past 6 months;
- Untreated severe stenotic or regurgitant valvular disease;
- Infiltrative cardiomyopathy (Fabry/HCM/sarcoid/amyloid, etc);
- Myocarditis;
Where this trial is enrolling
This trial has 1 sites across 1 state. Contact a site coordinator directly to start screening.
Virginia1 site
- University of VirginiaCharlottesville, Virginia
Timeline
Started enrolling: November 20, 2025. Expected completion: December 2029. Last updated on ClinicalTrials.gov: August 11, 2026.
Official source
Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked September 4, 2026. Confirm the current status there before you contact a site:
Other GLP-1 clinical trials
Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.
